JNJ Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Johnson & Johnson (JNJ) has recently formed a golden cross, a bullish technical indicator where the 50-day simple moving average crosses above the 200-day simple moving average. This pattern often signals strengthening long-term momentum. The stock is currently trading at $163.63, with a Fibonacci pivot point at $164.96, resistance levels at $168.33 and $170.40, and support levels at $161.60 and $159.53.
News and Fundamental Analysis:
Investment and Innovation: JNJ announced a $55 billion investment in the U.S. over the next four years, focusing on manufacturing, R&D, and technology. This investment is expected to create jobs and accelerate drug discovery, particularly in lung cancer treatment, where JNJ's RYBREVANT and LAZCLUZE combination therapy showed significant survival benefits in Phase 3 trials.
Analyst Sentiment: JNJ has a consensus Moderate Buy rating with a mean price target of $168.27, indicating a potential 2.84% upside from current levels.
Conclusion:
Based on the golden cross, positive news, and analyst sentiment, JNJ is expected to rise to $168 next week. This is a buy opportunity.
JNJ Similar Chart Price Prediction
The price of JNJ is predicted to go up 5.53%, based on the high correlation periods with SKM. The similarity of these two price pattern on the periods is 95.41%.
JNJ
SKM
Up: 5.53%Similarity: 95.41%
JNJ Revenue Forecast
JNJ EPS Forecast
JNJ FAQs
What is JNJ revenue forecast for next quarter？
What is JNJ eps forecast for next quarter？
JNJ VS S&P500
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.
Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.
JNJ Analyst's Forecast
Vamil Divan
Guggenheim
Hold
2025-03-12
Price Target
n/a
Downside
0%
Guggenheim downgraded Neumora Therapeutics (NMRA) to Neutral from Buy. with no price target following yesterday's announcement that Johnson & Johnson (JNJ) is discontinuing its Phase 3 VENTURA program testing aticaprant as an adjunctive treatment for major depressive disorder due to insufficient efficacy. Aticaprant's failure in MDD coming after Neumora's KOASTAL-1 failure with navacaprant "further weakens our conviction" on the validity of this mechanism of action in this indication, says the analyst, who has "limited confidence" on the potential success of navacaprant in MDD at this point.
Vamil Divan
Guggenheim
Hold
2025-03-10
Price Target
n/a
Downside
0%
Matt Miksic
Barclays
Hold
2025-01-28
Price Target
$159 → $166
Upside
+10.39%
